Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...

Analyst Luke Sergott of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $209.00.Don't ...

Mutual of America Capital Management LLC cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) ...

Dyne Therapeutics Inc.-0.13% $3.03B ...

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

周二，Piper Sandler维持对Sarepta Therapeutics (NASDAQ:SRPT)股票的增持评级，目标价保持在$200.00。该公司的立场是在竞争对手RGNX披露其用于杜氏肌营养不良症(DMD)的基因疗法RGX-202的最新进展之后做出的，该疗法正在进入关键性试验阶段。 更新内容包括研究第1/2阶段首五名患者的初步功能数据，显示功能改善和良好的安全性，未报告严重不良事件(S ...

On Tuesday, Piper Sandler sustained its Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) stock with a steadfast price target of $200.00. The firm's stance comes after a competitor ...

CAMBRIDGE, Mass., November 06, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2024.

CAMBRIDGE, Mass., November 06, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2024.

Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD), as it aims for a launch in the ...